ArticleFrontiers in immunology2026
Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL.
Jia Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.